KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.09
−3.51%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.08
From 52W high−99.20%
Volume31.49M
Market cap$1.93M
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataNov 4, 2026
Open
$0.08
From 52W high
−99.20%
Volume
31.49M
Market cap
$1.93M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
29.5
MomentumView details →
1D Return
−3.51%
YTD Return
−98.82%
SummaryUpdated Jun 1, 2026
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage pharmaceutical company founded in 2008 and headquartered in Newton, Massachusetts. The company went public in 2013 and specializes in developing and commercializing a novel class of cancer drugs called Selective Inhibitor of Nuclear Export (SINE) compounds. Karyopharm's lead product, XPOVIO (selinexor), is currently approved for multiple myeloma and diffuse large B-cell lymphoma, with the company advancing an ambitious pipeline of three Phase 3 trials targeting additional cancer indications including myelofibrosis and endometrial cancer.
Similar companies
Latest newsMore news →
Karyopharm Therapeutics entered into a $110 million super-priority senior secured debtor-in-possession term loan facility, including up to $55 million of new-money loans and second-out roll-up loans, subject to court approval.1d agoKaryopharm Therapeutics Inc. filed for bankruptcy.2d agoKaryopharm Therapeutics entered into a restructuring support agreement providing for a merger with Ayrmid Ltd. and a court-supervised sale process in which Ayrmid will serve as lead bidder.2d ago